World News

Sanofi will leverage Earendil’s artificial intelligence (AI)-powered drug discovery platform to support the design and development of multiple new therapeutic assets.

The collaboration aimed to support the distribution of Valneva’s single-dose vaccine, Ixchiq, in low- and middle-income countries (LMICs) across Asia.

Through this agreement, Sanofi will gain full ownership of Heplisav-B, a two-dose hepatitis B vaccine that received US approval in 2017 and European authorization in 2021.

Through this acquisition, J&J gains access to HLD-0915, a clinical-stage, once-daily oral therapy intended for the treatment of prostate cancer.

With this latest authorisation, individuals now have access to a long-acting option for prevention rather than daily pill-based regimens.

This deal gives Samsung Biologics its first manufacturing site in the US and reinforces its long-term commitment to serving the North American biopharmaceutical market.

The therapy is indicated for patients aged 12 years and older with severe asthma characterized by an eosinophilic phenotype.

Under the new guidance, only infants whose mothers test positive for hepatitis B or whose status is unknown will automatically receive the vaccine at birth.

Everest Medicines plans to deliver predictable near-term value through commercializing existing assets, forming business development partnerships, and achieving in-house research and development milestones.

The study compared the drug against bendamustine plus rituximab (BR) in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who had not received prior treatment and did not have 17p deletions.